B Cells

Melanoma uses weak immune cells to its advantage

Melanoma tumors create conditions that attract immunoglobulin G4 (IgG4), the B-cell antibody class least effective in activating immune response.

GVHD in pediatric HSCT patients: Clinical trials for Rituximab

GVHD in pediatric HSCT patients: Clinical trials for Rituximab

The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs